Pediatric Hepatic Impairment Dosing in FDA Approvals Between 2002 and 2024

Area of Science:

• Pharmacology and Therapeutics
• Pediatric Drug Development
• Hepatology

Background:

• Drug safety and efficacy are significantly affected by hepatic function, especially in pediatric patients.
• Evaluating hepatic impairment (HI) in pediatric drug development is challenging due to small patient populations and differing disease characteristics.
• Lack of standardized markers for assessing HI severity in children hinders drug development.

Purpose of the Study:

• To analyze adult and pediatric HI dosing recommendations in US FDA prescribing information (PI) and key pediatric drug databases (Lexicomp, Micromedex).
• To identify the clinical evidence supporting HI dosing recommendations for pediatric populations.
• To highlight the existing gaps in pediatric HI dosing guidelines.

Main Methods:

• Systematic review of 61 drugs with pediatric indications and 'hepatic' mentioned in the PI's Dosage and Administration section.
• Evaluation of pediatric-specific HI dosing recommendations and the evidence base cited.
• Comparison of recommendations across FDA PI, Lexicomp, and Micromedex.

Main Results:

• Only 8 out of 61 reviewed drugs provided pediatric-specific HI dosing recommendations, mostly based on the adult Child-Pugh classification.
• Evidence for these recommendations predominantly came from adult pharmacokinetic studies; only one drug had data from pediatric patients with mild HI.
• Lexicomp and Micromedex mirrored PI recommendations without citing additional supporting evidence.

Conclusions:

• A substantial gap exists in evidence-based dosing recommendations for pediatric patients with hepatic impairment.
• Current recommendations rely heavily on adult data, with limited pediatric-specific clinical evaluation.
• Modeling and simulation approaches may be crucial for addressing knowledge gaps in pediatric HI drug dosing in the future.